Vaccine · Immune activation, directed at SARS-CoV-2 spike protein and SARS-CoV-2 nucleocapsid protein · developed by GeoVax
GEO-CM04S1 is a vaccine built on a synthetic modified Vaccinia virus Ankara viral vector that encodes the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins. After administration, these antigens are expressed in cells and presented to the immune system, which may activate humoral and cellular responses. It is studied in COVID-19 and in patients with hematologic neoplasms including leukemia, lymphoma and multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04977024 | Phase 2 | COVID-19 Infection | Active not recruiting | GOVX |
| NCT04639466 | Phase 1/2 | COVID-19 Infection | Completed | GOVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hematopoietic and Lymphoid System NeoplasmLeukemiaLymphomaPlasma Cell MyelomaCOVID-19 Infection
Updated Oct 11, 2026. Something wrong or missing? Report it on the GOVX page.
See GOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GOVX catalysts and pipeline →